Royalty Pharma Plc
$ 55.87
1.54%
05 Jun - close price
- Market Cap 32,171,743,000 USD
- Current Price $ 55.87
- High / Low $ 55.94 / 55.00
- Stock P/E 29.41
- Book Value 15.53
- EPS 1.90
- Next Earning Report 2026-08-05
- Dividend Per Share $0.90
- Dividend Yield 1.63 %
- Next Dividend Date 2026-06-10
- ROA 0.06 %
- ROE 0.14 %
- 52 Week High 56.07
- 52 Week Low 32.67
About
Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York.
Analyst Target Price
$59.25
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-06 | 2026-02-11 | 2025-11-05 | 2025-08-06 | 2025-05-08 | 2025-02-11 | 2024-11-06 | 2024-08-08 | 2024-05-09 | 2024-02-15 | 2023-11-08 | 2023-08-08 |
| Reported EPS | 0.53 | 0.38 | 1.17 | 1.14 | 1.06 | 0.35 | 0.92 | 0.96 | 0.98 | 1.52 | 0.79 | 0.84 |
| Estimated EPS | 0.67 | 1.5 | 1.04 | 1.03 | 0.95 | 0.25 | 0.93 | 0.97 | 0.98 | 1 | 0.77 | 0.81 |
| Surprise | -0.14 | -1.12 | 0.13 | 0.11 | 0.11 | 0.1 | -0.01 | -0.01 | 0 | 0.52 | 0.02 | 0.03 |
| Surprise Percentage | -20.8955% | -74.6667% | 12.5% | 10.6796% | 11.5789% | 40% | -1.0753% | -1.0309% | 0% | 52% | 2.5974% | 3.7037% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-05 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 1.27 |
| Currency | USD |
Previous Dividend Records
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-06-10 | 2026-03-10 | 2025-12-10 | 2025-09-10 | 2025-06-10 | 2025-03-10 | 2024-12-10 | 2024-09-13 | 2024-06-14 | 2024-03-15 |
| Amount | $0.235 | $0.235 | $0.22 | $0.22 | $0.22 | $0.22 | $0.21 | $0.21 | $0.21 | $0.21 |
Next Dividend Records
| Dividend per share (year): | $0.90 |
| Dividend Yield | 1.63% |
| Next Dividend Date | 2026-06-10 |
| Ex-Dividend Date | 2026-05-15 |
Recent News: RPRX
2026-06-04 20:10:44
Royalty Pharma plc shareholders approved all proposals at its 2026 Annual General Meeting, with a strong quorum of 88.08% voting power. Key approvals included the election of all nine director nominees, executive compensation on a non-binding basis, and the ratification and re-appointment of Ernst & Young as auditors. Shareholders also granted the board authority for potential share repurchases and for allotting shares, including without pre-emption rights, indicating broad support for the company's governance and financial flexibility.
2026-05-29 17:40:04
This article provides a comprehensive overview of ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX) stock, including its current price, performance metrics, and key statistics such as market cap, P/E ratio, and dividend yield. It also covers technical and fundamental analysis ratings from ChartMill, recent earnings reports, analyst forecasts, and company details, highlighting its business model of funding biopharmaceutical innovation through royalties.
2026-05-28 21:08:57
Terrance P. Coyne, EVP and CFO of Royalty Pharma plc, sold 64,399 Class A Ordinary Shares for approximately $3.48 million on May 26, 2026, executed via a pre-arranged 10b5-1 trading plan. This sale occurred near the stock's 52-week high, with the company showcasing strong Q1 2026 financial performance. Despite the sale, Coyne retains significant direct and indirect holdings in Royalty Pharma.
2026-05-28 20:39:50
Terrance P. Coyne, EVP and CFO of Royalty Pharma plc, sold 64,399 Class A Ordinary Shares for approximately $3.48 million on May 26, 2026, executed via a pre-arranged 10b5-1 trading plan. This transaction occurred as the stock traded near its 52-week high after a significant 69% return over the past year. While the shares held by the LLC involved in the sale are now zero, Coyne retains other indirect and direct holdings in the company.
2026-05-28 20:39:50
Royalty Pharma's EVP & CFO, Terrance P. Coyne, through an affiliated entity (TPC RP EPA1 LLC), sold 64,399 Class A Ordinary Shares for approximately $3.48 million on May 26, 2026. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 24, 2026. While the selling entity now holds zero shares, Coyne maintains other direct and indirect holdings in the company.
2026-05-23 02:10:33
Royalty Pharma's EVP of Research & Investments, Marshall Urist, sold 13,684 Class A Ordinary Shares for $721,837 on May 20, 2026, as part of a prearranged trading plan. The sale occurred while RPRX stock was trading near its 52-week high, with the shares currently appearing overvalued according to InvestingPro analysis. Despite the sale, Urist retains significant direct and indirect holdings in the company.
